Novartis Challenges India's Patent Laws

In a highly controversial move, Swiss multinational Novartis is seeking to overturn India's intellectual property laws after the local patent office decided to decline the patent for Gleevec (imatinib), Novartis' groundbreaking cancer treatment. It is BMI's view that whatever outcome of this development, it will have a major impact on the global pharmaceutical industry. If India's authorities continue to ignore the patent, Novartis and many of its peers may exit the country and invest elsewhere, seriously damaging India's economic future. Conversely, if Novartis succeeds, the production of cheap generics in India could be permanently compromised, which could result in dire

To read the full article, please choose one of the following options: